Clinical trials: Metastatic Seminoma, open to volunteers
Hearing Loss, Metastatic Malignant Germ Cell Tumor
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with stage II-III testicular germ cell tumors that have spread from where…
- Conditions
- Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor
- Trial name
- NCT07218913
- Testing
- Audiometric Test, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Testicular Cancer, Seminoma
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph…
- Conditions
- Testicular Cancer, Seminoma, Quality of Life, De-escalation
- Trial name
- TESTIGO (NCT07498959)
- Testing
- primary RPLND for low-stage metasatatic seminoma, 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)
- Where
- Sweden
- Volunteers
- 160 people
- Sponsor
- Sahlgrenska University Hospital